A case of refractory Sézary syndrome with large-cell transformation responsive to brentuximab vedotin.
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- February 2014
has subject area
- 1103 Clinical Sciences (FoR)
- 1112 Oncology and Carcinogenesis (FoR)
- Aged, 80 and over (MeSH)
- Antineoplastic Agents (MeSH)
- Brentuximab Vedotin (MeSH)
- Cell Transformation, Neoplastic (MeSH)
- Female (MeSH)
- Humans (MeSH)
- Immunoconjugates (MeSH)
- Lymphoma, Large-Cell, Anaplastic (MeSH)
- Sezary Syndrome (MeSH)
- Skin Neoplasms (MeSH)
- Treatment Outcome (MeSH)
published in
- JAMA dermatology Journal